Prediction in the face of uncertainty: a Monte Carlo-based approach for systems biology of cancer treatment.
暂无分享,去创建一个
Andriani Daskalaki | Jian Li | Ralf Herwig | Hans Lehrach | Alexander Kühn | Christoph Wierling | Hendrik Hache | Elisabeth Maschke-Dutz | H. Lehrach | R. Herwig | C. Wierling | Hendrik Hache | A. Daskalaki | Elisabeth Maschke-Dutz | Jian Li | Svetlana Peycheva | Alexander Kühn | S. Peycheva
[1] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Sanjay Goel,et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.
[3] H. Kitano,et al. Computational systems biology , 2002, Nature.
[4] William A Weiss,et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.
[5] Axel Kowald,et al. Systems Biology - a Textbook , 2016 .
[6] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[7] H. Kitano,et al. A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.
[8] Axel Kowald,et al. Systems Biology in Practice: Concepts, Implementation and Application , 2005 .
[9] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[10] W. Kabsch,et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation , 1989, Nature.
[11] H. Kung,et al. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[12] L. Pustilnik,et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. , 1997, Cancer research.
[13] P. Harari,et al. Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results , 2004, Investigational New Drugs.
[14] J. Wityak,et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. , 1998, Bioorganic & medicinal chemistry letters.
[15] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[16] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[17] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[18] Robert A. Weinberg,et al. Creation of human tumour cells with defined genetic elements , 1999, Nature.
[19] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[20] M. Oshimura,et al. PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.
[21] S. Andreola,et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Y. Humblet. Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours , 2004, Expert opinion on pharmacotherapy.
[23] J. Baselga. The EGFR as a target for anticancer therapy--focus on cetuximab. , 2001, European journal of cancer.
[24] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[25] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[26] Y. Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.
[27] H. Lehrach,et al. Resources, standards and tools for systems biology. , 2007, Briefings in functional genomics & proteomics.
[28] F. Hobbs,et al. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase* , 1998, The Journal of Biological Chemistry.